Please login to the form below

Not currently logged in
Email:
Password:

FDA panel fails to back new use for AbbVie's Humira

Votes 12 to 1 against new use in spondyloarthritis

Humira - AbbottAbbVie is facing up to the likelihood it won't be able to expand the use of its biggest selling drug Humira in the US after an advisory panel to the US Food and Drug Administration (FDA) voted against an additional indication.

The panel, which advises the FDA, voted 12 to 1 that Humira (adalimumab) should not be available to market in the US for the treatment of spondyloarthritis – an inflammatory disease that affects the spine and causes back pain and swelling.

Instead, the panel of advisers requested that AbbVie conduct additional trials to support the efficacy of the drug in this condition, which is estimated to affect as many as 2.7 million adults in the US.

The FDA doesn't have to accept the panel's recommendation, but it often does, and a negative decision would be a blow for AbbVie as it looks to make the most of Humira's potential before the drug's patent expires in 2016.

Humira is already a huge seller, notching up more than $9bn during 2012 in its current autoimmune indications for rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, Ankylosing spondylitis and Crohn's disease.

However, AbbVie must handle both the looming threat of generic competition and new anti-inflammatory products, such as Pfizer's Xeljanz (tofactinib citrate) and Bristol-Myers Squibb's Orencia (abatacept), with these likely to impact Humira sales.

Nevertheless, the company is still positive for the drug's immediate future, stating in its inaugural guidance following its spin-out from Abbott in February this year that Humira sales in emerging markets will help to overall spur growth.

In Europe, Humira was approved for use in severe axial spondyloarthritis in July 2012, making it the first and only approved medication available for non-radiographic form of the condition.

25th July 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics